BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Core Insights - BioCryst Pharmaceuticals will present four abstracts at the ACAAI Annual Scientific Meeting, focusing on the APeX-P trial results for ORLADEYO in pediatric patients with hereditary angioedema [1][2] Group 1: Presentation Details - The abstracts will include a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with ORLADEYO in children aged 2 to <12 years [1] - Additional findings will address the psychosocial impact of hereditary angioedema on young patients and their caregivers [1] Group 2: Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent hereditary angioedema attacks in patients aged 12 years and older [4] - The drug functions as a plasma kallikrein inhibitor, with a recommended dosage of one capsule per day [4][5] Group 3: Safety and Efficacy - The safety and effectiveness of ORLADEYO for treating acute HAE attacks have not been established, and it should not be used for this purpose [6][10] - Common adverse reactions include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [7]